Dell'Olio Fabio, Siciliani Rosaria Arianna, Forte Marta, Capodiferro Saverio, Favia Gianfranco, Limongelli Luisa
Complex Operating Unit of Odontostomatology, Department of Interdisciplinary Medicine, Aldo Moro University, 70124 Bari, Italy.
Diagnostics (Basel). 2025 Apr 9;15(8):952. doi: 10.3390/diagnostics15080952.
The current study aims to show the diagnostic challenge of mandibular exposed necrotic bone in a patient with locally aggressive cutaneous squamous cell carcinoma of the lower lip and carrying risk factors for osteoradionecrosis and medication-related osteonecrosis of the jaws. In March 2023, an 80-year-old ex-farmer male patient complaining of feeding difficulty showed a 3 cm area of exposed bone in the left region of the mandible. In July 2020, the patient underwent an incisional biopsy of a lower labial cutaneous keratinizing squamous cell carcinoma, which developed within actinic cheilitis. The cancer was unresectable due to the extent of the local invasion; thus, the patient underwent radiotherapy. In February 2022, the cancer reached the left mandibular canal by completely infiltrating the homolateral canal of the mental nerve. Therefore, the oncologist prescribed cemiplimab and denosumab as palliative immunotherapy. The differential diagnosis included osteoradionecrosis, stage-III medication-related osteonecrosis of the jaws, and intraoral localization of the cutaneous squamous cell carcinoma. The oral surgeon performed a sequestrectomy under local anesthesia and antibiotic prophylaxis; a histological examination confirmed the hypothesis of medication-related osteonecrosis. The patient currently undergoes follow-up visits monthly; the combination of photobiomodulation therapy and cycles of antibiotics keeps the necrotic lesion steady, and the oncological therapy prevents the growth of the cutaneous squamous cell cancer. The current case supports the need for histological examination to resolve the diagnostic challenge of mandibular exposed necrotic bone and to differentiate among osteoradionecrosis, stage-III medication-related osteonecrosis of the jaws, and intraoral localization of cutaneous squamous cell carcinoma.
本研究旨在展示在下唇局部侵袭性皮肤鳞状细胞癌患者中,下颌骨暴露坏死骨的诊断挑战,该患者存在放射性骨坏死和药物相关性颌骨坏死的风险因素。2023年3月,一名80岁的前农民男性患者抱怨进食困难,其下颌骨左侧区域有3厘米的暴露骨区域。2020年7月,该患者接受了下唇皮肤角化性鳞状细胞癌的切开活检,该癌症发生于光化性唇炎。由于局部侵袭范围,该癌症无法切除;因此,患者接受了放疗。2022年2月,癌症通过完全浸润颏神经的同侧管到达左下颌管。因此,肿瘤学家开了西米普利单抗和地诺单抗作为姑息性免疫疗法。鉴别诊断包括放射性骨坏死、III期药物相关性颌骨坏死以及皮肤鳞状细胞癌的口腔内定位。口腔外科医生在局部麻醉和抗生素预防下进行了死骨切除术;组织学检查证实了药物相关性骨坏死的假设。患者目前每月接受随访;光生物调节疗法和抗生素疗程的联合使用使坏死病变保持稳定,肿瘤治疗防止了皮肤鳞状细胞癌的生长。本病例支持需要进行组织学检查,以解决下颌骨暴露坏死骨的诊断挑战,并区分放射性骨坏死、III期药物相关性颌骨坏死以及皮肤鳞状细胞癌的口腔内定位。